India Drug-Pricing Agency Tries New Tactic To Collect Overcharges
This article was originally published in PharmAsia News
India's drug-pricing authority has stepped up its efforts to get pharmaceuticals to pay the fines assessed them for charging too much. The National Pharmaceutical Pricing Authority is developing new guidelines that allow local government authorities to collect fines from drug makers in the areas where they actually have assets. The practice has been to refer cases to district authorities on a case-by-case basis, but the new NPPA guidelines strengthen the government's ability to collect the assessments. The NPPA already has used the new method to collect on overcharges in five cases. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.